Elevated CXCR6 expression has been observed in various cancer tissues, including prostate cancer [32], pancreatic ductal adenocarcinoma [33], and schwannoma [34], indicating that CXCR6 could be a promising therapeutic target. This evidence concerns the gene CXCR6 and pancreatic ductal adenocarcinoma.